https://wikimd.org/index.php?action=history&feed=atom&title=CRLX101 CRLX101 - Revision history 2026-04-26T19:36:00Z Revision history for this page on the wiki MediaWiki 1.44.2 https://wikimd.org/index.php?title=CRLX101&diff=6500636&oldid=prev Prab: CSV import 2025-03-17T06:44:29Z <p>CSV import</p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 06:44, 17 March 2025</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l28">Line 28:</td> <td colspan="2" class="diff-lineno">Line 28:</td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{Drug-stub}}</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{Drug-stub}}</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{No image}}</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{No image}}</div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">__NOINDEX__</ins></div></td></tr> <!-- diff cache key wikimd4:diff:1.41:old-6216780:rev-6500636:php=table --> </table> Prab https://wikimd.org/index.php?title=CRLX101&diff=6216780&oldid=prev Prab: CSV import 2025-02-10T09:33:41Z <p>CSV import</p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:33, 10 February 2025</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l27">Line 27:</td> <td colspan="2" class="diff-lineno">Line 27:</td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Chemotherapy]]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Chemotherapy]]</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{Drug-stub}}</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{{Drug-stub}}</div></td></tr> <tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">{{No image}}</ins></div></td></tr> <!-- diff cache key wikimd4:diff:1.41:old-5902214:rev-6216780:php=table --> </table> Prab https://wikimd.org/index.php?title=CRLX101&diff=5902214&oldid=prev Prab: CSV import 2024-06-12T22:59:44Z <p>CSV import</p> <p><b>New page</b></p><div>&#039;&#039;&#039;CRLX101&#039;&#039;&#039; is an investigational [[nanoparticle-drug conjugate]] (NDC) designed for the treatment of various types of [[cancer]]. It is developed by [[Cerulean Pharma Inc.]] and is currently undergoing clinical trials to evaluate its efficacy and safety.<br /> ==Mechanism of Action==<br /> CRLX101 is a [[camptothecin]]-based NDC that targets [[topoisomerase I]], an enzyme critical for [[DNA replication]] and [[transcription]]. By inhibiting topoisomerase I, CRLX101 induces [[DNA damage]] and [[apoptosis]] in cancer cells. The nanoparticle formulation allows for enhanced delivery and retention of the drug in [[tumor]] tissues, potentially improving its therapeutic index.<br /> ==Clinical Development==<br /> CRLX101 has been evaluated in multiple [[clinical trials]] for various cancer types, including [[renal cell carcinoma]], [[ovarian cancer]], and [[small cell lung cancer]]. Early-phase trials have shown promising results in terms of [[tumor]] response and [[progression-free survival]].<br /> ===Phase I Trials===<br /> The initial Phase I trials focused on determining the [[maximum tolerated dose]] (MTD) and [[dose-limiting toxicities]] (DLTs) of CRLX101. These studies also provided preliminary evidence of the drug&#039;s anti-tumor activity.<br /> ===Phase II Trials===<br /> Subsequent Phase II trials aimed to further assess the efficacy and safety of CRLX101 in specific cancer types. These trials have explored the use of CRLX101 both as a monotherapy and in combination with other [[chemotherapeutic agents]].<br /> ==Potential Benefits==<br /> The nanoparticle formulation of CRLX101 offers several potential benefits over traditional chemotherapy, including:<br /> * Enhanced drug delivery to tumor tissues<br /> * Reduced systemic toxicity<br /> * Improved pharmacokinetics and biodistribution<br /> ==Related Pages==<br /> * [[Nanoparticle-drug conjugate]]<br /> * [[Topoisomerase I]]<br /> * [[DNA replication]]<br /> * [[Apoptosis]]<br /> * [[Renal cell carcinoma]]<br /> * [[Ovarian cancer]]<br /> * [[Small cell lung cancer]]<br /> * [[Clinical trial]]<br /> <br /> [[Category:Experimental cancer drugs]]<br /> [[Category:Nanomedicine]]<br /> [[Category:Chemotherapy]]<br /> {{Drug-stub}}</div> Prab